The initial euphoria over the GLP-1 drugs like Ozempic has mellowed, but catalysts expected in 2025 could energize investor interest in the stocks.
Related Posts
Bank of America CEO says it could launch stablecoin if regulations allow: CNBC Crypto World
On today’s episode of CNBC Crypto World, bitcoin and ether add to Tuesday’s losses while XRP rises. Plus, Bank of America CEO Brian Moynihan tells […]
Trump and Harris portfolios to play the election winner, according to Strategas Research
The U.S. presidential election is just a few days away, and Strategas believes some select names are due to perform well depending on the outcome.